IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis

Abstract

These results suggest that IDH1 mutations are recurrent molecular aberrations in patients with myelodysplastic syndromes, and may become useful as a poor risk marker in these patients. These findings await validation in prospective trials.